Get to know our clinical trials
clinical trials evaluating the safety and efficacy of autologous transfer of T lymphocytes with enhanced RLT expression in subjects with solid or hematologic malignancies.
THE PURPOSE OF THIS SCREENING STUDY IS TO PERFORM TWO TESTS TO DETERMINE THE EXISTENCE OF PARTICULAR TYPES OF BIOMARKERS (PROTEINS OR RNA) IN YOUR BODY TO SEE IF YOU WOULD BE ELIGIBLE TO PARTICIPATE IN A TREATMENT STUDY. NO TREATMENT IS GIVEN IN THIS SCREENING STUDY. THE RESULTS OF THIS SCREENING STUDY WILL HELP YOUR DOCTOR DECIDE IF YOU ARE ELIGIBLE TO MOVE FROM SCREENING TO A MODIFIED T-LYMPHOCYTE TREATMENT STUDY.
Technical Summary
- SCREENING PROTOCOL TO DETERMINE TUMOR ANTIGEN EXPRESSION AND HLA SUBTYPE TO ESTABLISH SUITABILITY FOR PARTICIPATION IN CLINICAL TRIALS TO EVALUATE THE SAFETY AND EFFICACY OF AUTOLOGOUS TRANSFER OF T LYMPHOCYTES WITH ENHANCED LTR EXPRESSION IN SUBJECTS WITH SOLID OR HEMATOLOGIC MALIGNANCIES.
- Code EudraCT: -
- Protocol number: ADP-0000-001
- Promoter: Adaptimmune LLC
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.